Adherex Technologies Inc. Expands Phase II ADH-1 Trial To Include Three Additional Canadian Sites

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--March 2, 2006--Adherex Technologies Inc. (AMEX:ADH)(TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company has initiated three additional sites in Canada for its Phase II clinical trial of ADH-1 (Exherin(TM)): BC Cancer Agency - Vancouver Centre in Vancouver, British Columbia, Cross Cancer Institute in Edmonton, Alberta, and QEII Health Sciences Centre in Halifax, Nova Scotia, bringing the total number of clinical sites for the trial to six, including the current centers in Toronto, Montreal and Ottawa.

MORE ON THIS TOPIC